Supplementary Figure 1 to 7 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

<p>Supplemental Figure S1. Validation of anti-CD73 antibody used for IHC and analysis of cutaneous melanoma metastases. Supplemental Figure S2. Next-generation sequencing based analysis of bisulfite conversion to assess CpG island methylation in the NT5E (CD73) promoter region. Supplemental Figure S3. c-Jun and FOSL1 protein expression in MaMel melanoma cell lines. Supplemental Figure S4. Functional role of AP-1 sites in the NT5E (CD73) genomic region for the induction of CD73 by c-Jun. Supplemental Figure S5. IHC analysis of CD73 expression by melanoma cells in mouse ACT relapse melanomas. Supplemental Figure S6. Comparison of the 'proliferative' melanoma phenotype gene set with the cell proliferation associated E2F and MYC gene sets. Supplemental Figure S7. Graphical abstract of CD73 expression in melanoma phenotype switching.</p>